IP Library › Granted Patent US 10,287,303
Granted Patent B2
US 10,287,303 · App. 15/853,310 · Granted May 14, 2019

Compositions and methods for inhibiting arginase activity

Inventors: Eric B. Sjogren (Mountain View, CA); Jim Li (San Francisco, CA); Lijing Chen (Cupertino, CA); Roland J. Billedeau (Santa Clara, CA); Timothy F. Stanton (Daly City, CA); Michael Van Zandt (Guilford, CT); Darren Whitehouse (Westbrook, CT); Gunnar E. Jagdmann, Jr. (Branford, CT); Lene Raunkjær Petersen (Værløse, DK)
Assignee: Calithera Biosciences, Inc.
C07F5/025A61K31/4245A61K31/69A61K39/3955A61K39/39558A61K45/06A61P35/00A61P35/02C07K16/2818A61K2039/507A61K2300/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,287,303
App. No.
15/853,310
Granted
May 14, 2019
Kind
B2
Abstract

The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.

Claims (36)

1. A compound having a structure of formula (I*):

or a pharmaceutically acceptable salt thereof;

wherein:

R 1 is methyl; and

R 4 is H or (C 1 -C 6 )alkyl.

2. The compound of claim 1 , having a structure of the following formula:

3. The compound of claim 1 , having a structure of the following formula:

4. The compound of claim 1 , wherein R 4 is (C 1 -C 6 )alkyl.

5. The compound of claim 4 , wherein R 4 is methyl, ethyl, propyl, or isopropyl.

6. A compound having the following structure:

or a pharmaceutically acceptable salt thereof.

7. A compound having the following structure:

or a pharmaceutically acceptable salt thereof.

8. A solid pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

9. The compound of claim 6 , having the following structure:

or a pharmaceutically acceptable salt thereof.

10. The compound of claim 6 , having the following structure:

or a pharmaceutically acceptable salt thereof.

11. The compound of claim 7 , having the following structure:

or a pharmaceutically acceptable salt thereof.

12. The compound of claim 7 , having the following structure:

or a pharmaceutically acceptable salt thereof.

13. The compound of claim 1 , wherein R 4 is H.

14. The compound of claim 2 , wherein R 4 is H.

15. The compound of claim 2 , wherein R 4 is (C 1 -C 6 )alkyl.

16. The compound of claim 15 , wherein R 4 is methyl, ethyl, propyl, or isopropyl.

17. The compound of claim 3 , wherein R 4 is H.

18. The compound of claim 3 , wherein R 4 is (C 1 -C 6 )alkyl.

19. The compound of claim 18 , wherein R 4 is methyl, ethyl, propyl, or isopropyl.

20. A solid pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.

21. A solid pharmaceutical composition comprising a compound of claim 4 and a pharmaceutically acceptable carrier.

22. A solid pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable carrier.

23. A solid pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable carrier.

24. A solid pharmaceutical composition comprising a compound of claim 10 and a pharmaceutically acceptable carrier.

25. A solid pharmaceutical composition comprising a compound of claim 12 and a pharmaceutically acceptable carrier.

26. A solid pharmaceutical composition comprising a compound of claim 18 and a pharmaceutically acceptable carrier.

Assignments (6)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 28, 2023
From: CALITHERA BIOSCIENCES, INC.
To: PRECISION PHARMACEUTICALS, INC.
Reel/Frame 064091/0777 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2019
From: SJOGREN, ERIC B.; LI, JIM; CHEN, LIJING; BILLEDEAU, ROLAND J.; STANTON, TIMOTHY F.; GROSS, MATTHEW I.; PARLATI, FRANCESCO
To: CALITHERA BIOSCIENCES, INC.
Reel/Frame 048616/0958 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2019
From: VAN ZANDT, MICHAEL; WHITEHOUSE, DARREN; JAGDMANN, GUNNAR E., JR.
To: NEW ENGLAND DISCOVERY PARTNERS, LLC
Reel/Frame 048616/0995 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2019
From: NEW ENGLAND DISCOVERY PARTNERS, LLC
To: CALITHERA BIOSCIENCES, INC.
Reel/Frame 048617/0029 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2019
From: NCK A/S
To: CALITHERA BIOSCIENCES, INC.
Reel/Frame 048617/0076 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2019
From: PETERSEN, LENE RAUNKJAER
To: NCK A/S
Reel/Frame 048617/0113 →
Continuity (3)
Provisional Application 62438092 · Dec 22, 2016
Provisional Application 62439614 · Dec 28, 2016
Related Publication 20180222926A1 · Aug 9, 2018
Cited By (1)
US 12,187,725